Glucose Metabolism Disorders
Conditions
Keywords
GIP, GIP receptor antagonist
Brief summary
Delinieation of GIP's effects during a meal in humans using GIP receptor antagonisation.
Detailed description
Aim: To evaluate the role of GIPR signalling in postprandial physiology, including lipid, bone and glucose homeostasis, using a naturally occurring GIP fragment, which antagonises the GIPR. Twelve healthy men (age 18-70 years, BMI 19-27 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin\[9-39\], C) GIP-A + Exendin\[9-39\], or D) saline (placebo).
Interventions
Sponsors
University of Copenhagen
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal kidney function, liver function and hemoglobin levels.
Exclusion criteria
* Medication, Diabetes type 1 or 2, BMI \> 27, first degree relatives with Type 2 Diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C-peptide levels | 180 minutes | Serum C-peptide AUC. Primary outcome changed during the inclusion period (original = insulin levels) due to risk of misinterpretation/diverse hepatic insulin extraction). |
Countries
Denmark
Outcome results
None listed